Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504893 | 0.86 | MAOB (0.51) | MAOBPARP10NR4A2SPHK2MAOA | |
| SCHEMBL3505960 | 0.85 | MAOB (0.48) | MAOBSPHK2MAOASCN9AP4HTM | |
| SCHEMBL3506405 | 0.81 | MAOB (0.65) | MAOBPARP10NR4A2SPHK2MAOA | |
| SCHEMBL3505355 | 0.81 | P4HTM (0.72) | MAOBPARP10NR4A2MAOAP4HTM | |
| SCHEMBL4426020 | 0.81 | MAOB (0.55) | MAOBPARP10NR4A2SPHK2MAOA | |
| SCHEMBL3503835 | 0.80 | P4HTM (0.60) | MAOBPARP10NR4A2MAOASCN9A | |
| SCHEMBL3505676 | 0.78 | GRM5 (0.63) | MAOBPARP10NR4A2SPHK2 | |
| SCHEMBL963386 | 0.75 | SPHK2 (0.67) | MAOBPARP10NR4A2SPHK2MAOA | |
| SCHEMBL4425971 | 0.74 | MRGPRX4 (0.58) | MAOBPARP10NR4A2SPHK2 | |
| SCHEMBL12924825 | 0.74 | HPGDS (0.56) | MAOBSCN9AP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1474394-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | claimed |
| US-6667327-B2 | Pyridine amido derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | claimed |
| US-20030158235-A1 | Pyridine amido derivatives | F.HOFFMAN-LA ROCHE AG (CH) | 2003-08-21 | — | — | US | claimed |
| WO-2003066596-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1474394-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6667327-B2 | Pyridine amido derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030158235-A1 | Pyridine amido derivatives | F.HOFFMAN-LA ROCHE AG (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003066596-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158235-A1 | Pyridine amido derivatives | MAOB, MAOA, XDH | MAOB 1/4885PARP10 663/4885NR4A2 2930/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885PARP10 833/4885NR4A2 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.